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Recent designer drugs, also known as “legal highs,” include substituted cathinones (e.g., mephedrone, methylone,
and methylenedioxypyrovalerone, often referred to as “bath salts”); synthetic cannabinoids (SCs; e.g., Spice); and
synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation
and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has
become popular among members of the military. Acute toxicity is common and often manifests with a constellation of
psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple
deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind
when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints.
Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term
treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.
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There is growing international concern about the syn-
thetic analogs of controlled substances being manufac-
tured and distributed to circumvent drug laws and evade
interdiction. These compounds are referred to as “designer
drugs” or “legal highs” [1] (see Table 1). They are sub-
stances with psychotropic effects that are intentionally
marketed and distributed for recreational use by exploiting
inadequacies of existing controlled substance legislation
[2]. Nonchemists can easily synthesize the compounds
with readily available raw materials, or they can obtain the
synthetic compounds directly [3]. The chemicals are often
packaged with labels that inaccurately describe product
contents, which may vary substantially regarding chemical
content and concentration [4]. Labels often include the
phrase, “not for human consumption,” in an attempt to
avoid legal risk. Designer drug use has expanded in the
past decade—especially among young adults—leading to
significant problems for some users.* Correspondence: Michael.F.Weaver@uth.tmc.edu
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unless otherwise stated.Although the emerging designer drug trend was ini-
tially recognized by increasing calls to US poison control
centers [5], the incidence of designer drug problems in
emergency departments (EDs), hospitals, and other med-
ical settings is largely unknown. Only a small percentage
of those using designer drugs will come into contact
with the health-care system, but consequences of use
can be severe. Familiarity with designer drugs can help
clinicians recognize common adverse reactions and life-
threatening consequences. This article will focus on three
newer designer drugs: substituted cathinones (commonly
referred to as “bath salts”), synthetic cannabinoids (SCs;
e.g., “Spice”), and synthetic hallucinogens (e.g., “N-bomb”).Epidemiology of emerging designer drugs
Designer drug use is most prevalent among young
adults, primarily males in their mid to late 20s, but ran-
ging from teens to adults 40 years of age [6-9]. Those
who use designer drugs tend to be single and have lower
levels of education and income [10,11]. The use of SC
products may be higher in select subpopulations, such
as in regular cannabis users [12], university students
[13], and dance club attendees [7]. Among high school
seniors, the annual prevalence of SC consumption was. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Designer drugs
Drug class Chemical name Chemical origin Slang names





Cannabinoid JWH-018; JWH-073; JWH-250 Laboratory of J.W. Huffman Spice, K2, K9, Aroma, herbal highs,
Scooby Snax
CP 47,497; CP 47,497-C8; CP 59,540; cannabicyclohexanol Pfizer laboratory
HU-210 Hebrew University laboratory




Hallucinogen 25I-NBOMe Free University of Berlin N-bomb, Solaris, Smiles, Cimbi-5
25B-NBOMe
25C-NBOMe
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rates among high school seniors dropped to 8 percent in
2013, but remained more prevalent than any illicit drug
except cannabis (annual use of cannabis remained un-
changed) [11]. Bath salt use appears comparably lower
than SC, with 1 percent use among the same sample
[11]. Overall use of hallucinogens remains very low in
the United States, and the epidemiology of synthetic hal-
lucinogens is not currently captured in national surveys.
The growing popularity of designer drugs relates to
factors such as novelty, marketing, and accessibility. De-
signer drug packaging is colorful and attractive, with
enticing names for the products to attract younger indi-
viduals to try them [14,15]. Designer drugs are sold
without age restriction, which also makes them attractive
to younger individuals. Widespread availability, includ-
ing purchase via the Internet, has contributed to ex-
panded use. Marketing designer drug products as “legal
high” alternatives may contribute to the perception of
greater safety or purity compared to traditional illicit
drugs, which could promote increased consumption
[16]. Risk factors for adolescent experimentation with
and problems resulting from designer drug use include
parents with substance use disorders (SUDs), poor fam-
ily relationships, poor discipline, or high family conflict;
adolescents involved with foster care or the criminal
justice system are also at risk [17].
In response to rising designer drug use and conse-
quences, a series of state and federal initiatives have
been enacted during the past several years prohibiting
the manufacture, sale, and possession of many designer
compounds. Although designer drug use has persisted
despite regulatory efforts [11,12,18], there may be a na-
tional trend toward reduced consumption of somedesigner drugs [11]. Use appears to be growing in some
subpopulations—including the US military—perhaps to
evade detection by urine drug screening [18]. Designer
drug use is especially prevalent among those in the mili-
tary who abuse other substances. Patients presenting for
consequences of designer drug use will frequently be
using more than a single drug.
Bath salts
Pharmacology
Most designer stimulants are derivatives of cathinone, the
primary active alkaloid in the natural herbal stimulant khat
(Catha edulis). Three of the primary substituted cathi-
nones sold as bath salts include: mephedrone, methylene-
dioxypyrovalerone (MDPV), and methylone [2]. The
designer substituted cathinones are part of the larger family
of stimulants that includes amphetamine, methampheta-
mine, and methylenedioxymethamphetamine (MDMA, or
“ecstasy”).
Substituted cathinones appear to increase extracellular
levels of the monoamine neurotransmitters dopamine,
norepinephrine, and serotonin via facilitation of extracel-
lular release and reuptake inhibition [3,19,20]. These
neurochemical effects likely account for similar sym-
pathomimetic, subjective, and reinforcing effects of the
substituted cathinones. The pharmacology and product
effects (such as increased alertness, tachycardia, and po-
tential for psychosis) appear similar to stimulants such
as amphetamines and cocaine.
Acute clinical effects
Most designer stimulants are taken intranasally but may
be consumed orally or via intravenous or intramuscular
injection [7,9]. Mephedrone is not suitable for smoking.
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nutes after dosing, peak at 45-90 minutes, last 2-3 hours,
and then decrease over 6-12 hours. Users may consume
multiple doses during a session to prolong the desired
effects [17].
Commonly reported effects that overlap with cocaine,
amphetamine, and MDMA include increased energy,
alertness, concentration, sexual stimulation, empathy, talk-
ativeness, mood enhancement, euphoria, and decreased
appetite [6,17].
Adverse psychiatric effects
Most users report intermittent adverse effects [7,13].
Acute toxicity may be associated with larger binge con-
sumption and exposure to multiple substances. Acute
agitation is a hallmark of toxicity [21]. Psychosis may be
pronounced, with patients experiencing paranoia, hallu-
cinations (primarily visual), and delusions.
Repeated dosing of substituted cathinone likely leads
to tolerance [22], which is indicated indirectly by the as-
sociation between frequency of use and greater amount
consumed [7]. Binges have been reported with signifi-
cant successive dosing of mephedrone [7]. Withdrawal
effects reported among chronic users include: tiredness,
insomnia, difficulty concentrating, irritability, depres-
sion, and nasal congestion [6]. Some users experience a
dependence syndrome, with cravings and compulsive
use [6,7,13,23]. The liability for development of a severe
diagnosable SUD from use of chronic substituted cathi-
none could be quite high [21].
Adverse physiologic effects
Bath salts were largely responsible for a doubling in an-
nual stimulant/sympathomimetic-related toxicology cases
reported, from 6 percent in 2010 to 12 percent in 2011
[5]. Commonly reported effects include diaphoresis, palpi-
tations, muscle tension or spasms, and bruxism (jaw
clenching) [6,17]. Most individuals exhibit autonomic
hyperactivity on exam (e.g., tachycardia, hypertension).
Nasal-specific adverse effects include epistaxis and sore
nasal passages, mouth, and throat [13].
Sympathomimetic toxicity is manifested by neuro-
logical and cardiovascular clinical features. The use of
bath salts has been associated with cardiac arrhythmias
and myocarditis [18]. Significant hyponatremia has been
reported with mephedrone use (similar to that seen with
MDMA), which is likely due to a combination of sweating,
electrolyte loss, and antidiuretic hormone secretion [24].
More serious renal impairment includes acidosis and
acute renal failure associated with rhabdomyolysis. Deaths
have been reported with mephedrone and MDPV [21].
In addition to the cathinone effects, contaminants
could play a role in adverse effects. Product analysis
studies have demonstrated adulteration with benzocaine,lidocaine, procaine, caffeine, or even controlled drugs
such as cocaine, amphetamine, ketamine, and piperazine
compounds [4,8,25]. Adulterants with stimulant proper-
ties could potentiate the effects of bath salts and raise
toxicity risk by increasing the sympathetic effects or
chances of cardiac arrhythmias [26].
Empirical or prospective data are limited regarding
long-term adverse physiological effects of substituted
cathinone use. However, neurotoxicity is plausible (e.g.,
monoamine depletion, neuronal degradation) along with
development of physiological dependence among regular




The primary cannabinoid in cannabis is delta-9-tetra-
hydrocannabinol (THC), a partial agonist at the CB1 re-
ceptor, which is located throughout the human body,
especially the central nervous system. SCs used recreation-
ally may be full or partial CB1 agonists that were originally
synthesized for research purposes in different university
laboratories. Frequently, the SC-containing products used
recreationally include individual or mixtures of different
SC compounds sprayed on psychoactively inert pulverized
plant matter of virtually unknown content to resemble
potpourri or incense [27]. The term Spice is now generally
applied to all products containing SC, regardless of brand-
ing [2]. Compared to THC, SCs are often more potent
and efficacious CB1 agonists and may have a longer half-
life, all of which may lead to greater cannabinomimetic
toxicity [28]. There is substantial variability in product
composition and wide concentration ranges for SC [29],
which can also add to the risk of toxicity.
Acute clinical effects
SCs are primarily smoked via a joint, bowl, or water
pipe, although they can be consumed orally or intrana-
sally [28]. Acute effects are similar to cannabis, including
alteration in mood, conjunctival injection, and tachycar-
dia [30]. Effects are reported to start within 10 minutes
after inhalation, and most effects appear to dissipate 2-6
hours after use [30,31].
Adverse psychiatric effects
Adverse psychological effects are common with the use
of SC products [12] and may include anxiety, trouble
thinking clearly, agitation, paranoia, and delusions [32].
Reports indicate that SC can provoke acute psychosis—
which appears more likely in users with underlying bio-
logic vulnerability due to family history of psychosis—as
well as worsen pre-existing chronic psychotic disorders
[18,33,34]. Psychotic symptoms can persist for a signifi-
cant time, from 1 week to 5 months in reported cases [33].
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stitute to relieve cannabis withdrawal symptoms, likely
indicating cross-tolerance between SC and THC [12,30].
SCs appear to serve as a sufficient cannabis substitute,
especially when cannabis is unavailable [12]. Case re-
ports have documented withdrawal symptoms after SC
product use, as well as a dependence syndrome, similar
to those seen with cannabis [35].
Adverse physiologic effects
Commonly reported side effects include dry mouth,
lightheadedness, and headache [12,36]. Other unwanted
negative physiological effects include diaphoresis, tremors,
dystonia, and dyspnea [32]. Tachycardia is common with
SC use (similar in cannabis users), due potentially to re-
duced peripheral vascular resistance and the subsequent
need to maintain cardiac output by increasing heart rate,
rather than due to a direct sympathetic effect. The tachy-
cardia may be severe, along with hypertension and chest
pain [18]. One case report of significant bradycardia with
chest pain has also been reported [37].
Several SC compounds (specifically JWH-018, JWH-
073, and AM-2201) have been implicated as a cause of
cannabinoid hyperemesis syndrome, which is a chronic
disorder that was originally characterized among chronic
cannabis users who experienced cyclic episodes of vomit-
ing and abdominal pain relieved by bathing or showering
with hot water [38]. However, cannabis-related hyperem-
esis syndrome is quite rare. To the extent that SC might
be more likely to cause nausea and vomiting, such symp-
toms could help to differentiate intoxication between the
two [39].
Severe SC-related toxicity requiring emergency treat-
ment has included seizures, acute renal failure, and myo-
cardial infarction [30,40-43]. Deaths have been reported
with SC due to a cardiac ischemic event and extreme
anxiety resulting in suicide [44].
There are no studies of the long-term effects of SC.
Smoking SC products results in the inhalation of burned
unidentified plant material as well as SC, which may
have adverse effects on the pulmonary system, so some
sources recommend vaporization instead of smoking as
a cannabinoid delivery method [45]. Additionally, JWH-
018 may be a carcinogen [46]; anecdotal data indicate
the development of tolerance and a withdrawal syn-
drome with chronic use [30].
Synthetic hallucinogens
Pharmacology
Synthetic designer hallucinogens gained popularity after
the 1991 publication of Alexander Shulgin’s book, PIH-
KAL, A Chemical Love Story. PIHKAL, an acronym for
“Phenethylamines I Have Known and Loved,” details the
synthesis of over 200 psychedelic compounds [47]. The“2C” series of hallucinogenic phenethylamines, first de-
scribed by Shulgin, share a similar chemical structure;
the term “2C” is derived from the two carbon molecules
between the benzene ring and the amino group. These
compounds have a similar structure to MDMA and pro-
duce hallucinations through serotonergic stimulation.
The substituted phenethylamine 4-iodo-2,5dimethoxy-
N-(2-methoxybenzyl) phenethylamine (25I-NBOMe) is a
relatively new derivative of the 2C series of phenethyla-
mines. 25I-NBOMe is one of several N-benzyl phenethy-
lamines that have become popular since October 2011
when the U.S. Drug Enforcement Administration issued
a temporary Schedule I status on many of the com-
pounds marketed as bath salts [48]. 25I-NBOMe is a
highly potent, high-affinity agonist of the serotonin 2a
(5HT2a) receptor [49] that was originally synthesized for
research on the serotonin receptor [50]. Other hallu-
cinogenic NBOMe drugs include 25C-NBOMe and 25B-
NBOMe [51].
Acute clinical effects
Use of 25I-NBOMe in both liquid and powder form has
been reported, with many potential routes of administra-
tion, including inhalation of vapor, nasal insufflation,
oral ingestion, sublingual/buccal administration, and
intravenous injection [51-53]. The most common use is
oral/sublingual/buccal, but nasal insufflation is not un-
usual [51]. When administered by the oral/oral mucosal
route, 25I-NBOMe is ingested as a pill or absorbed as
powder or on blotter paper. Use of the drug generally
occurs in a single administration of a small quantity,
about 0.1 gram, or “cap.” Clinical effects can occur rap-
idly after nasal use and generally peak in 20 minutes. A
wide duration-of-action range of 3-13 hours has been re-
ported [51]. In reported cases of clinical toxicity, agita-
tion persisted for several days [50,52].
The reported effects of 25I-NBOMe are similar to
those of prototypical serotonergic hallucinogens such as
lysergic acid diethylamide or psilocybin [54]. Users re-
port hallucinations with a varying degree of stimulating
effects. Depersonalization has been reported as well. In
contrast to prototypical serotonergic hallucinogens, 442
users responding to an Internet survey reported that
25I-NBOMe had greater “negative effects while high,”
but with more “value for money” [51].
Adverse psychiatric effects
In addition to the anticipated visual and auditory halluci-
nations, many users experience psychiatric consequences,
prompting them to access medical services. Some of these
consequences include delirium, agitation, aggression, vio-
lence, paranoia, dysphoria, severe confusion, and self-
harm [50,52,53,55,56]. Some patients have presented with
a serotonergic or sympathetic toxidrome consisting of an
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violence [47]. In one case, a reportedly hallucinogen-
naïve 19-year-old man died from a multiple-story fall
after ingesting 25I-NBOMe and developing paranoid
and bizarre behavior [55]. In another fatal case, a 21-
year-old male driver who ingested 25I-NBOMe devel-
oped sudden rage, pulled his car off the road, and began
to destroy the inside of the vehicle before dying from an
unknown cause [56].
Adverse physiologic effects
Tachycardia, hypertension, and mydriasis are frequently
described in the few clinical reports of 25I-NBOMe
users [50,52,53]. Hyperreflexia and clonus have also been
reported in several cases [52,53]. Seizures occurred in
many of the cases that eventually required medical atten-
tion [52,53]. Severe toxicity has included hyperthermia,
pulmonary edema, and death from trauma [50,52,55,56].
In one report of a fatal exposure, a 15-year-old girl became
unresponsive after ingesting 25I-NBOMe outside a rave;
on arrival at a local hospital she was in asystole with a rec-
tal temperature of 39.9°C [56]. Long-term physiologic ef-
fects are not known.
Drug testing challenges
Urine or serum toxicology screens are unable to detect
all of the designer drugs that have been synthesized,
posing a major diagnostic and monitoring challenge for
clinicians. Although laboratory testing is expanding,
widespread standardized designer drug testing is not yet
available in most clinical practice settings and laboratories.
The analytical challenge is compounded by heterogeneity
in designer drug product contents, concentration, and
chemical constituents, all of which may vary between and
within products [57].
Illicit manufacturers have demonstrated remarkable
flexibility in altering the psychoactive components of de-
signer drugs to evade regulation and detection [2,58]. It
is common practice by drug designers to modify func-
tional groups, change substitutions, and alter moieties of
substances in a rapid and iterative process to evade legal
restriction [2]. This practice also poses significant chal-
lenges for detection of compounds or metabolites through
urine drug screening.
Individuals frequently report that the lack of detection
on standard urine drug screening tests is a reason for
designer drug product use [21]. For example, popula-
tions under criminal justice supervision may use de-
signer drugs to evade detection by probation officers.
Among the US military, where most soldiers referred for
addiction treatment are identified through urine drug
screening, SCs are consumed by those seeking cannabis-
like mood-altering effects, but with much lower risk of
detection [59].Even though most emerging designer drugs will not be
picked up on routine urine drug screening in a health-care
setting, collection of urine is still valuable clinically to test
for unreported, co-occurring substance use. A general la-
boratory screening battery of urine or serum should be
sent to screen for common drugs of abuse [26]. This helps
the clinician to be aware of potential toxicity due to drug
interactions, or to the need for closer or prolonged moni-
toring due to the presence of other, nondesigner sub-
stances. When comprehensive designer drug testing is
unavailable or pending, familiarity with the most common
designer drugs and other substances of abuse in a given
locality can help clinicians rapidly recognize intoxication
and begin management of serious complications.
Screening and assessment
The challenges with designer drug analytic testing neces-
sitate vigilance to recognize use. Young adults are the
most common demographic among those seeking emer-
gency medical services related to designer drug use [60].
Hence, clinicians should consider direct inquiry about
designer drug use, particularly among young adults pre-
senting for acute medical care with signs or symptoms
that could indicate substance-related toxicity. Since de-
signer drugs are not detected by routine drug screens,
health-care providers relying solely on laboratory testing
may be misled to believe that illicit drugs have not been
used [32]. Conversely, the presence of routinely detect-
able illicit substances does not rule out the presence of
designer drugs, since polysubstance use is typical in the
population using designer drugs. Clinicians should be
alert for inconsistencies between observed and expected
intoxication syndrome from a self-reported or detected
class of drugs. Such discrepancies could indicate recent
designer drug use.
Clinicians can be alert for clinical clues based on varia-
tions in patient presentation that may help identify de-
signer drug use (see Table 2). Conjunctival injection is
an indicator of SC intoxication, as well as other cannabis
products. Some patients presenting for emergency treat-
ment may still have the package that contained the designer
drug. This can be examined for possible identification of
common brand names for a specific class of designer drug
(see Table 1) and, potentially, any remaining content can
be sent to a laboratory for analysis. Internet sites may be
helpful for identification of specific substances ingested
due to their rapidly changing appearance [61]. However,
the lack of research-based information on the adverse ef-
fects of designer drugs has led to the emergence of a range
of websites that may or may not provide accurate informa-
tion [62]. The presence of paraphernalia such as a pipe for
smoking could indicate designer drug or other smokable
drug use, and a strong smell of perfume or cologne may
be an attempt to mask the smell of recent smoking.
Table 2 Indicators of designer drug use
Body system Finding Medical indication Drug (s)
General Hyperthermia Intoxication Synthetic hallucinogens, bath salts
Head & neck Conjunctival injection Recent use Synthetic cannabinoids
Smoky chemical smell on breath Recent smoking Any smoked designer drug
Epistaxis Intranasal use Bath salts, synthetic hallucinogens
Nasal septal perforation Intranasal use Bath salts
Poor dentition Inadequate oral hygiene Bath salts
Jaw clenching, teeth grinding (bruxism) Intoxication Bath salts
Cardiac Tachycardia Recent use Any designer drug
Hypertension Recent use Any designer drug
Chest pain Cardiac ischemia, myocarditis Bath salts, synthetic cannabinoids
Renal Acute kidney injury Recent use Synthetic cannabinoids
Gastrointestinal Nausea, vomiting Recent use or withdrawal syndrome Synthetic cannabinoids
Enlarged and/or tender liver Acute hepatitis Any injected designer drug
Musculoskeletal Muscle spasms Intoxication Bath salts
Limb swelling and pain Rhabdomyolysis Bath salts, synthetic hallucinogens
Skin Diaphoresis Recent use Bath salts
Ecchymosis Recent use or intoxication Synthetic hallucinogens
Fresh needle marks, track marks Injection drug use Any injected designer drug
Neurologic Clonus Recent use Synthetic hallucinogens
Seizures Intoxication Bath salts, synthetic hallucinogens,
synthetic cannabinoids
Psychiatric Agitation Recent use Any designer drug
Hallucinations Recent use Any designer drug
Psychosis Intoxication Any designer drug
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dent, particularly among patients with a history of SUD,
those who are undergoing mandated urine testing (e.g.,
criminal justice supervisees), or among those who have re-
ported a history of designer drug use of a different chem-
ical class [63]. Different classes of designer drugs may be
used concurrently, which could increase the incidence of
adverse effects and toxicity. It is helpful for clinicians to
ask about specific products by name, or perhaps “syn-
thetics” in general, since patients may not be aware of des-
ignations used by medical personnel, or of different street
names for similar products. For each affirmative response,
follow-up questions should be asked about frequency, pat-
terns of use, and subjective effects. Careful inquiry about
subjective effects could help provide insight into the de-
signer drug class, particularly when the brand-compound
association is less well established and with wide variation
in contents. Although Table 1 lists brand names along
with the designer drug compound or class, the list is not
comprehensive; there are likely thousands of different
trade-name brands sold internationally [29].
Further clinical inquiry should include specific ques-
tions about factors associated with designer drug useand the potential consequences, whether related to med-
ical, interpersonal difficulties, or financial or legal prob-
lems. Chronic designer drug use may lead to physiologic
dependence with tolerance and abstinence-related with-
drawal, as well as a designer drug use disorder [21,29].
Comprehensive inquiry about such factors regarding the
patient’s designer drug use helps the clinician make an
initial determination about potential severity and pro-
vides insight into treatment needs.
Among patients presenting for acute medical compli-
cations of designer drug use, routine laboratory testing
should include—in addition to standardized urine drug
testing—a complete blood cell count and complete
metabolic panel. Cardiac enzymes should be obtained if
cardiac symptoms are present. Creatine phosphokinase
is helpful if rhabdomyolysis is suspected on the basis of
severe muscle spasms, swelling and pain in the extrem-
ities, or severe seizures. Additional diagnostic studies
may be selected on the basis of the initial presentation.
Management of acute intoxication
No specific antidotes are available for designer drug tox-
icity. Activated charcoal is not useful unless there has
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toms appear self-limited and resolve within one to several
days with supportive treatment. Unpleasant psychological
effects of acute intoxication, such as anxiety, agitation, or
paranoia may be managed with supportive treatment. Pla-
cing the distraught user in a quiet environment and main-
taining gentle contact is often sufficient until the acute
effects subside [64].
Psychosis due to synthetic cannabinoids (SC) and 25I-
NBOMe intoxication have been managed with monitored
observation [52,65]. For psychopathological clinical fea-
tures, benzodiazepines have been used to treat anxiety,
agitation, and seizures [8,52,53,65]. Antipsychotics are
second-line agents for agitation [8], due to the lowered
seizure threshold with use of cathinone and phenethyla-
mine designer drugs [66]. Sedation may be required if the
patient is markedly agitated and at risk for harm to self or
health-care staff [63]. Since some designer drug-associated
psychosis may be severe and require prolonged inpatient
treatment, psychiatric consultation is indicated, in particu-
lar for those with persistent symptoms.
Abrupt discontinuation of stimulants or hallucinogens
does not cause gross physiologic sequelae, so they are
not tapered off or replaced with a cross-tolerant drug
during medically supervised withdrawal [26]. Abrupt dis-
continuation of SC could result in withdrawal symptoms
such as nausea and irritability, similar to that with
cannabis cessation. However, there is no indication for
pharmacologic replacement (e.g., dronabinol), since SC
withdrawal is not life-threatening. Patients can be
treated with supportive care by intravenous fluids and
antiemetics if necessary. If marked psychiatric symptoms
persist longer than one or more weeks after discontinu-
ation, the patient should be evaluated carefully to deter-
mine whether he or she has a co-occurring primary
psychiatric disorder, which then should be treated with
specific therapy [67]. Treatment of prolonged anxiety,
depression, or psychosis is the same as when these con-
ditions are not associated with recent designer drug use.
For a significant number of patients, the high level of
illness severity warrants admission to critical care. Intox-
icated patients should be placed initially on continuous
cardiac monitoring with pulse oximetry and frequent
neurological assessments [63]. Adequate administration
of intravenous fluids is encouraged to assure good urine
output, as these patients often are dehydrated [63]. Fluid
administration in the presence of rhabdomyolysis can
help prevent acute renal failure. Intensive monitoring al-
lows for early detection and intervention for serious
consequences, such as myocardial infarction.
Patients may present with concurrent ingestion of
drugs with different pharmacological profiles, including
both stimulant and depressant drugs. Clinicians should
be alert for an unexpected response to a therapeuticintervention or to a change in patient presentation as
one type of designer drug wears off and ongoing intoxi-
cation with another class of designer drug is revealed.
This may require some flexibility in treatment due to
changes in mental or cardiovascular status.
Treatment of designer drug addiction
Hospitalization for the adverse effects of designer drugs
affords an excellent opportunity (teachable moment) for
advising patients to decrease their substance use and for
engaging them in treatment [68]. Health-care provider
awareness and patient education are cornerstones of
public health initiatives [2] to confront new challenges
presented by designer drugs. Simple admonitions to stop
are sometimes helpful if the diagnosis is made early, but
in most cases are insufficient [69]. Many patients who
use designer drugs may be ambivalent about changing
behavior, so the clinician should express empathy with-
out confrontation, which shows respect for the patient’s
autonomy. Providing appropriate, accurate information
about the potential risks of designer drugs and encour-
aging healthy choices can help patients make the best in-
formed decision about changing behavior. Physicians
should involve the patient proactively in the process of
problem-solving, while reminding the patient of respon-
sibility for all actions. The responsibility of the practi-
tioner is to motivate the patient to seek recovery from
designer drug use instead of blaming the patient for be-
ing unmotivated to change [69]. Accurate information
about the relative risks and unknown harms of these
products helps a patient make an informed choice about
continuing to use particular products, to make a quit at-
tempt, or to seek more specific addiction treatment.
Although prospective treatment data are limited, once
a designer drug use disorder diagnosis is made, acute
and long-term treatment is likely necessary [70]. Recov-
ery from SUD in general is possible, and those who are
treated have less disability than those who remain un-
treated [71]. Long-term treatment of designer drug use
disorders likely involves similar components to that of
other types of addiction treatment, including behavioral
components, such as individual and group counseling
with cognitive-behavioral therapy, motivational enhance-
ment therapy, and 12-Step self-help group facilitation.
Family members should be considered as part of the
treatment program, in particular when treating adoles-
cents or young adults. Unfortunately, pharmacologic
treatment data to guide management of those with de-
signer drug use disorders are unavailable.
Patients identified with SUD in the ED or hospital
inpatient setting should be provided with information
linking them to local community addiction treatment
resources. In the United States, physicians certified in
the treatment of addictive disorders can be found
Weaver et al. Addiction Science & Clinical Practice  (2015) 10:8 Page 8 of 9through the American Society of Addiction Medicine
(www.asam.org) or the American Academy of Addic-
tion Psychiatry (www.aaap.org). At times, it may be
more expedient and cost effective to refer the patient
to a nonphysician counselor [64], which can be found
through the National Association for Alcohol and Drug
Abuse Counselors’ website (www.naadac.org). Sub-
stance abuse treatment services in the United States can
also be located via the Substance Abuse and Mental
Health Services Administration Behavioral Health Services
Treatment Locator (http://findtreatment.samhsa.gov).
Treatment of designer drug SUD is challenging for
several reasons. Designer drugs consist of several differ-
ent classes of substances, which vary in their psycho-
logical and physiological effects. Treatment is often
difficult due to the young age of most users and the pos-
sibility of concurrent polysubstance use. The pattern of
use is usually intermittent in social settings, so it may be
perceived as less of a problem. Clinicians should be
knowledgeable of and prepared to provide treatment for
very different combinations, such as what occurs with
club drug use [72]. A treatment environment with a sup-
portive structure can be helpful. Addiction treatment is
cost effective [73], and even multiple episodes of treat-
ment are worthwhile. It can be very rewarding for any
health-care practitioner to assist a patient who was im-
paired by addiction return to normal functioning in
society.Conclusions
Bath salts, SC, and 25I-NBOMe are relatively new de-
signer drugs that continue to remain popular drugs of
abuse, especially among young adults. Though chem-
ically different, they are similar in that they are groups
of synthetic analogs that continue to change in attempts
to avoid legal issues and detection on drug tests. They
are also similar in that adverse reactions are common,
especially clinically significant psychotic reactions. De-
tection of these drugs with urine tests is challenging, so
clinicians should consider designer drug use in young
adults with agitation and psychosis. Treatment is pri-
marily supportive, and benzodiazepines may be benefi-
cial. When those who use designer drugs come into
contact with the health-care system, it is important for
clinicians to provide linkage to additional, specific treat-
ment for the substance use disorder.Competing interests
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